Table 3.
Clinical treatments and outcomes of 728 patients with COVID-19.
| Covariates | Levels | Normal IL-6 (n = 608) n (%) | Elevated IL-6 (n = 120) n (%) | All patients (n = 728) | P value |
|---|---|---|---|---|---|
| n (%) | |||||
| Drugs | |||||
| Antibiotic | 149 (24.51%) | 66 (55.00%) | 215 (29.53%) | <0.001 | |
| Antiviral drugs | 271 (44.57%) | 75 (62.50%) | 346 (47.53%) | <0.001 | |
| Antimalarial drugs | 47 (83.93%) | 5 (16.67%) | 52 (60.47%) | <0.001 | |
| Anticoagulants | 30 (4.93%) | 46 (38.33%) | 76 (10.44%) | <0.001 | |
| Corticosteroid | 27 (4.44%) | 23 (19.17%) | 50 (6.87%) | <0.001 | |
| Vitamin C | 112 (18.42%) | 36 (30.00%) | 148 (20.33%) | 0.004 | |
| Traditional Chinese medicine | 540 (88.82%) | 98 (81.67%) | 638 (87.64%) | 0.03 | |
| Oxygen support | |||||
| Low-flow nasal cannula | 76 (85.39%) | 21 (60.00%) | 97 (78.23%) | 0.002 | |
| Non-invasive ventilation or high-flow nasal cannula | 13 (14.61%) | 10 (28.57%) | 23 (18.55%) | <0.001 | |
| Invasive mechanical ventilation | 0 (0.00%) | 3 (8.57%) | 3 (2.42%) | <0.001 | |
| ECMO | 0 (0.00%) | 1 (2.86%) | 1 (0.81%) | <0.001 | |
| CT scores | 1–4 | 27 (51.92%) | 20 (40.00%) | 47 (46.08%) | 0.227 |
| 5–7 | 25 (48.08%) | 30 (60.00%) | 55 (53.92%) | ||
| Disease progression | |||||
| Stableness/Hospitalization | 3 (0.50%) | 3 (2.73%) | 6 (0.84%) | <0.001 | |
| Improvement/Recover | 601 (99.34%) | 101 (91.82%) | 702 (98.18%) | ||
| Death | 1 (0.17%) | 6 (5.45%) | 7 (0.98%) | ||
| Length of hospital stay, d, median (IQR) |
20.0 (14.0–25.0) | 20.0 (15.0–28.0) | 20.00 (14.00–26.00) | 0.243 | |
| ICU care | 5 (0.82%) | 24 (20.00%) | 29 (93.55%) | 0.007 | |
| Severity on admission | |||||
| Mild | 117 (19.24%) | 20 (16.67%) | 137 (18.82%) | <0.001 | |
| General | 365 (60.03%) | 44 (36.67%) | 409 (56.18%) | ||
| Severe | 122 (20.07%) | 43 (35.83%) | 165 (22.66%) | ||
| Critical | 4 (0.66%) | 13 (10.83%) | 17 (2.34%) | ||
| Severity at worst | |||||
| Mild | 0 | 0 | 0 | <0.001 | |
| General | 325 (53.5%) | 18 (15.0%) | 343 (47.18%) | ||
| Severe | 273 (45.0%) | 76 (63.3%) | 349 (48.01%) | ||
| Critical | 9 (1.5%) | 26 (21.7%) | 35 (4.81%) |